MRE-269 98%
cas: 475085-57-5 — see every product listed under this CAS number, including other names
MRE-269 98% (CAS 475085-57-5) is a chemical reagent available from Chemat. Available pack sizes: 1mg, 5mg, 10mg, 50mg, 100mg, 250mg, 1g, 5g. Offered by: Ambeed.
| brand | Ambeed |
|---|---|
| catalog number | A209226-1mg |
| cas | 475085-57-5 |
| size | 1mg |
Documents:
Safety Data Sheet (MSDS)
Need more information?
Ask us about this product — we're happy to help.
Available pack sizes
| brand | size | price | |
|---|---|---|---|
| Ambeed | 1mg | 175.69 Pln | |
| Ambeed | 5mg | 197.94 Pln | |
| Ambeed | 10mg | 220.19 Pln | |
| Ambeed | 50mg | 292.50 Pln | |
| Ambeed | 100mg | 337.00 Pln | |
| Ambeed | 250mg | 392.62 Pln | |
| Ambeed | 1g | 743.06 Pln | |
| Ambeed | 5g | 2411.81 Pln | |
| Ambeed | 25g | 8029.94 Pln |
properties
| purity | 98% |
|---|---|
| delivery time | 1-2 weeks |
| ambeed catalog no. | A209226 |
ACT-333679 is a member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as a vasodilator agent, a drug metabolite, a platelet aggregation inhibitor, an orphan drug and a prostacyclin receptor agonist. It is a monocarboxylic acid, an ether, an aromatic amine, a sulfonamide, a member of pyrazines and a tertiary amino compound.
Source: ChEBI
| Molecular formula | C25H29N3O3 |
|---|---|
| Molecular weight | 419.5 g/mol |
| IUPAC name | 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid |
| InChIKey | OJQMKCBWYCWFPU-UHFFFAOYSA-N |
| SMILES | CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3 |
Computed by PubChem (NCBI)
Synonyms:
{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid, 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic acid, (4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy)acetic acid, 2-(4-((5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino)butoxy)acetic acid, 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid, Laselipag, (4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid, Selexipag active metabolite, 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid, 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid